Login or Register
Biomedical Learning Institute Taught by the Experts
Thought Leaders
Biomedical Learning Institute
Please Note: The Oncology Learning Center has changed its name to Biomedical Learning Institute
About Us
Purpose and Goals
The Biomedical Learning Institute (BLI) is a multidisciplinary provider of continuing education for the healthcare team, including, physicians, pharmacists, nurses and other allied healthcare professionals. The continuing education that is planned by the BLI is based upon research that it conducts through needs assessments that identify Practice Gaps of intended learners. All continuing education activities of the BLI are measured for the achievement of educational outcomes in terms of improvement in professional knowledge, competence, implementation of changes in performance-in-practice, and/or patient outcomes.

The purpose of the BLI's CME/CE Program is to help improve patient care and patient outcomes by:

  1. providing physicians with continuing medical education activities designed to improve their knowledge, competence and performance in diagnosis and treatment of patients.
  2. providing pharmacists with continuing education activities designed to improve their knowledge in accordance with the ”Scope of Contemporary Pharmacy Practice: Roles, Responsibilities, and Functions of Pharmacists and Pharmacy Technicians”; published by the Council on Credentialing Pharmacy in February 2009.
  3. providing nurses and other allied healthcare professionals with continuing education as it relates to cancer to improve their knowledge.
  4. facilitating learners in the development and implementation of their own individual strategies to close identified gaps in their professional practices.
  5. providing learners with continuing educational content that is evidence-based, fair balanced, scientifically objective, references best practices as indicated in peer reviewed published data and other statistics, and is free of any commercial bias.
  6. producing change in learner behavior—or to validate current behaviors—consistent with best practices using educational outcomes measures as metrics.
Content
The Biomedical Learning Institute (BLI) initially has focused its CME/CE interventions with clinical content that addresses identified professional pharmacy knowledge-based Practice Gaps in the treatment, management and prevention of cancer, including oncology, hematology and supportive care. In early 2011 the BLI has begun to officially expand its content focus into other therapeutic areas beginning with the cardiovascular, endocrine/metabolic, central nervous and genito/urinary systems, infectious disease, immunology, hepatology, gynecology, the skin, and pulmonology.
Target Audience
The learners that the Biomedical Learning Institute (BLI) targets for its CME/CE activities correspond to those practitioners identified in the needs assessment process. The scope of practice of the targeted audience for any CME/CE activity is a key component of planning continuing education at the BLI. This is accomplished through a deep understanding of the current practice of targeted learners by utilizing our own staff and external experts with extensive experience in the core clinical area of cancer, and will expand to include staff and external experts in the other therapeutic areas mentioned above as we expand our scope of content. Expert perspectives are obtained for our CME/CE interventions from course chairs, faculty, and relevant specialty and federal and local guidelines, and, the results of other qualitative and quantitative research regarding our targeted learners.

Currently: BLI is currently an ACCME-accredited provider of continuing education for physicians. For the past several years BLI has focused mainly on cancer continuing education and has been preparing for comprehensive expansion of its educational interventions into other therapeutic areas and for other healthcare professionals in 2011.

2011: BLI now routinely develops CME/CE for physicians, pharmacists, nurses and other allied healthcare professionals involved in the treatment, care and management of patients with diseases other than cancer, including diseases involving the skin, infectious disease, the cardiovascular, endocrine and central nervous systems, immune, pulmonary, and also diseases of the respiratory, hepatic, gynecologic and genito/urinary systems. In July 2011, BLI expects to become an ACPE-accredited provider of continuing education for pharmacists. BLI submitted its application to ACPE in January 2011. Similarly, BLI expects to become an ANCC-accredited provider of continuing education for nurses in December 2011. BLI submitted its initial application to ACPE in April 2011.

Types of Activities
The selection of format and design of CME/CE reflects the overall needs assessment process and the commitment of the BLI to provide continuing education that changes behavior and sustains those changes. When possible, opportunities for sequential education are sought to enable those results through longitudinal multimodal curricula such as our personalized therapies curriculum that has been ongoing for an expanding number of disorders for 5 years. In general, however, the BLI has the capacity to deliver CME/CE through the following types of activities:
  1. Live activities, including full-day courses, symposia, workshops and virtual, live, Web-based activities on the Internet.
  2. Home-study, Internet-enduring material activities, including print, CD-ROM and DVDs, Internet CE, and resource kits. (resource kits may include slide compendia, practical application tools, clinical cases and patient tools.)

Because the BLI understands the complex environment of clinicians' practices and their mindset in which each of their patients is unique and requires the pharmacists and other healthcare professionals to devise a unique treatment plan, our educational activities focus on equipping learners with knowledge and options for the application of patient care strategy rather than dictating inflexible recommendations. Thus, whenever possible, our learning formats utilize adult learning principles, are highly interactive, including patient case-study-based learning, and debates by experts on controversial relevant practice issues. In addition, BLI activities endeavor to incorporate other interactive discussions into activities in order to optimize learner involvement. And whenever possible, BLI utilizes formats that incorporate multiple exposures of learners to the same content through the use of enduring materials derived from live events.

Expected Results of the Biomedical Learning Institute CME/CE Program: Measuring Educational Effectiveness
Expected results of changes in learners' knowledge, competence and practice performance following educational activities are measured by utilizing a number of targeted educational outcomes' measures. We hold our educators and their activities to the following metrics:
  1. Measurement of improvement in performance-in-practice are determined by responses to telephone interviews conducted approximately three to four months post-activity and focused on key changes in behavior anticipated by the activity's planners and identified by the learners in written statements on the post-activity Evaluation Forms. Additional follow-up outcomes measurements via on-line Web surveys of past BLI educational activity participants help determine retention of newly acquired knowledge, competence or changed practice behaviors which can be used in the assessment of Practice Gaps in the BLI's planning process.
  2. Measurements of improvement in knowledge: Specific, detailed questions are used on each post-activity Evaluation Form and measure learner commitment to behavioral change as anticipated by planners. Hand-held, interactive Audience Response System (ARS) devices are used pre- and post-activity, and instant feedback is projected on the screen during all BLI live courses.
  3. Measurements of improvement in competence are measured either by responses to questions associated with case studies administered at the conclusion of the activity or through response to a paired-question approach using ARS in which the learner is queried on application of knowledge and competence to patient scenarios prior to and subsequent to the learning experience.
  4. All of the above-mentioned techniques help BLI determine whether the learner is able to develop strategies to incorporate new knowledge or skills into existing practice.
  5. When either knowledge, competence and/or learner performance-in-practice are not adequately improved as measured by outcomes questionnaires and or qualitative interviews of learners the barriers that prevented them from being implemented are identified so that more effective future activities can be developed and implemented.
  6. When designated, improvement in patient outcomes will be assessed through the observational findings of learners based on their patients that present with relevant medical problems in the ensuing time between the questionnaire and the activity.
  7. General learner satisfaction is measured for all elective metrics in terms of learner response to post–activity evaluation questions relating to achievement of educational objectives, the quality of the faculty, the ability of the activity to address learners needs for participating in the activity, in their experience of whether the activity was presented without commercial bias.

The BLI staff analyzes all assessments and evaluations and presents their results to management to assure that each educational activity is consistent with the CME/CE mission, and, to make improvements to the CME/CE program on an ongoing basis.

© 2012 Biomedical Learning Institute
1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Registration Phone: 214.269.2014 • Fax: 214.866.0311
Contact Us
Disclaimer: The material published on the Biomedical Learning Institute(BLI) Web site reflects the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the BLI, the CME provider, or the commercial supporters providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified physician should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any BLI materials. Click here for our Privacy Policy.